A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications.

in Leukemia & lymphoma by Larry Milshteyn, Anton Villamejor, Akil Merchant, Joseph Lownik

TLDR

  • The study describes a new way to study a type of cancer called Peripheral T-cell Lymphoma (PTCL). The researchers made a special type of cancer cell called LM-23 from a mouse. They then gave this cancer cell to mice and found that it grew very quickly and didn't respond to certain treatments. The study shows that LM-23 is a good way to study PTCL and could help researchers find new treatments for this cancer.

Abstract

Peripheral T-cell Lymphoma (PTCL) represents a heterogenous group of aggressive non-Hodgkin Lymphomas with poor prognostic outcomes and limited treatment options. The development and refinement of therapeutic strategies for PTCL are impeded by a paucity of reliable preclinical models that accurately mimic the disease's pathophysiology. There is a dire need for more physiologically relevant models for PTCL. Here we describe a spontaneousCD8peripheral T-cell lymphoma cell line (LM-23) derived from a 12-week-old female Balb/cJ mouse. Both intravenous and subcutaneous administration of this cell line to syngeneic Balb/cJ mice resulted in rapid establishment of tumor growth. CHOP and anti-PD1 treatment both displayed no benefit to mice in regulating tumor growth. Such results along with its phenotypic characteristics, rapid growth, and metastatic behavior in syngeneic mice highlight its value in studying the elusive disease and discovery of novel therapeutics.

Overview

  • The study focuses on developing a preclinical model for Peripheral T-cell Lymphoma (PTCL) that accurately mimics the disease's pathophysiology. The authors describe a spontaneous CD8 peripheral T-cell lymphoma cell line (LM-23) derived from a 12-week-old female Balb/cJ mouse. The study aims to evaluate the efficacy of intravenous and subcutaneous administration of this cell line in syngeneic Balb/cJ mice and assess the impact of CHOP and anti-PD1 treatment on tumor growth. The primary objective is to establish a reliable preclinical model for PTCL that can aid in the development of novel therapeutics.

Comparative Analysis & Findings

  • The study found that both intravenous and subcutaneous administration of the LM-23 cell line resulted in rapid establishment of tumor growth in syngeneic Balb/cJ mice. CHOP and anti-PD1 treatment showed no benefit in regulating tumor growth. These findings suggest that the LM-23 cell line is a valuable preclinical model for PTCL that accurately mimics the disease's pathophysiology and can aid in the discovery of novel therapeutics.

Implications and Future Directions

  • The study highlights the importance of developing physiologically relevant preclinical models for PTCL to aid in the discovery of novel therapeutics. The LM-23 cell line can be used to study the elusive disease and evaluate the efficacy of different treatment options. Future research should focus on identifying the molecular mechanisms underlying the development and progression of PTCL and developing targeted therapies based on these mechanisms. Additionally, the LM-23 cell line can be used to study the immune response to PTCL and evaluate the efficacy of immunotherapies.
Read Full Article